Lantheus Holdings, Inc.
LNTHAPI behind this page
LNTH FY 2025 request
Playground key active
/api/financials?ticker=LNTH&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 1,541,609 | 1,533,910 | +0.5% |
Show Product Lines breakouts |
|||
| DEFINITY | 330,248 | 317,792 | +3.9% |
| License and royalty revenues | 34,036 | 9,128 | +272.9% |
| Neuraceq | 51,447 | — | — |
| Other precision diagnostics | 24,616 | 24,231 | +1.6% |
| Product | 1,507,573 | 1,524,782 | -1.1% |
| PYLARIFY | 989,116 | 1,057,834 | -6.5% |
| Strategic partnerships and other revenue | 59,379 | 38,182 | +55.5% |
| TechneLite | 86,803 | 95,487 | -9.1% |
| Total precision diagnostics | 493,114 | 437,510 | +12.7% |
| Total radiopharmaceutical oncology | 989,116 | 1,058,218 | -6.5% |
Show Geography breakouts |
|||
| Non Us | 82,728 | 49,223 | +68.1% |
| US | 1,458,881 | 1,484,687 | -1.7% |
| Cost of Revenue | 599,657 | 545,619 | +9.9% |
| Gross Profit | 941,952 | 988,291 | -4.7% |
| Sales & Marketing | 178,691 | 177,940 | +0.4% |
| General & Administrative | 275,121 | 193,689 | +42.0% |
| Research & Development | 177,308 | 168,098 | +5.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 177,308 | 168,098 | +5.5% |
Show Asset Acquisition breakouts |
|||
| Life Molecular Imaging, RM2 Technology | 11.2 | — | — |
| Operating Expenses Before Gain Loss On Sale Of Assets | 631,120 | 539,727 | +16.9% |
| Operating Income | 310,832 | 456,979 | -32.0% |
| Interest Expense | 19,749 | 19,669 | +0.4% |
| Equity Securities Fv Ni Gain Loss | 8,617 | 43,564 | -80.2% |
| Other Non-Operating Income (Expense) | -31,326 | -37,231 | +15.9% |
| Income Before Taxes | 313,792 | 430,977 | -27.2% |
| Income Tax Expense (Benefit) | 80,233 | 118,535 | -32.3% |
| Net Income | 233,559 | 312,442 | -25.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 233,559 | 312,442 | -25.2% |
| EPS (Basic) | 3.46 | 4.52 | -23.5% |
| EPS (Diluted) | 3.41 | 4.36 | -21.8% |
| Wtd Avg Shares (Basic) | 67,489 | 69,199 | -2.5% |
| Wtd Avg Shares (Diluted) | 68,443 | 71,651 | -4.5% |
| Comprehensive Income | 233,867 | 311,864 | -25.0% |
| Other Comprehensive Income | 308 | 222 | +38.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 308 | 222 | +38.7% |
| Foreign Currency Transaction Gain Loss Before Tax | 1,006 | 733 | +37.2% |
| Net Income Loss Available To Common Stockholders Basic | 233,559 | 312,442 | -25.2% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 359,121 | 912,814 | -60.7% |
| Accounts Receivable | 358,640 | 321,258 | +11.6% |
| Inventory | 64,674 | 68,025 | -4.9% |
| Income Taxes Receivable | 15,387 | 8,177 | +88.2% |
| Other Assets Current | 21,400 | 16,359 | +30.8% |
| Assets Of Disposal Group Including Discontinued Operation Current | 80,742 | — | — |
Show Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations breakouts |
|||
| SPECT Business · Building | 48.1 | — | — |
| SPECT Business · Construction In Progress | 6.2 | — | — |
| SPECT Business · Land | 6.5 | — | — |
| SPECT Business · Machinery, equipment and fixtures | 37.5 | — | — |
| SPECT Business · Software And Software Development Costs | 0.5 | — | — |
| Total Current Assets | 899,964 | 1,326,633 | -32.2% |
| Non-Current Assets | |||
| Goodwill | 239,517 | 61,189 | +291.4% |
| Deferred Tax Assets | 109,196 | 170,233 | -35.9% |
| Other Non-Current Assets | 50,044 | 44,237 | +13.1% |
| Total Assets | 2,227,399 | 1,980,340 | +12.5% |
| Property, Plant & Equipment | 163,686 | 176,798 | -7.4% |
| Operating Lease Right-of-Use Assets | 30,975 | 36,083 | -14.2% |
| Intangible Assets | 473,779 | 161,761 | +192.9% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Currently marketed products | 409,787 | 79,767 | +413.7% |
| Customer Relationships | 12,124 | 21,095 | -42.5% |
| Developed Technology Rights | 42,771 | 50,692 | -15.6% |
| Licensing Agreements | 8,066 | 9,030 | -10.7% |
| Trademarks | 1,031 | 1,177 | -12.4% |
| Other Assets | |||
| Equity Securities Fv Ni And Without Readily Determinable Fair Value | 42,213 | 39,489 | +6.9% |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 163,686 | 176,798 | -7.4% |
| Intangible Assets Net Excluding Goodwill | 722,779 | 161,761 | +346.8% |
| Current Liabilities | |||
| Current Portion of Long-Term Debt | 738 | 974 | -24.2% |
| Accounts Payable | 42,906 | 34,560 | +24.1% |
| Accounts Payable And Other Accrued Liabilities Current | 267,307 | 204,992 | +30.4% |
| Liabilities Of Disposal Group Including Discontinued Operation Current | 22,468 | — | — |
| Total Current Liabilities | 333,419 | 240,526 | +38.6% |
| Non-Current Liabilities | |||
| Asset Retirement Obligations Noncurrent | 138 | 23,344 | -99.4% |
| Deferred Tax Liabilities | 54,246 | — | — |
| Business Combination Contingent Consideration Liability Noncurrent | 73,255 | — | — |
| Other Non-Current Liabilities | 107,866 | 63,180 | +70.7% |
| Total Liabilities | 1,137,602 | 892,329 | +27.5% |
| Operating Lease Liabilities | 50,016 | 53,185 | -6.0% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 568,678 | 565,279 | +0.6% |
| Stockholders' Equity | |||
| Common Stock | 718 | 709 | +1.3% |
| Additional Paid In Capital Common Stock | 888,320 | 817,972 | +8.6% |
| Treasury Stock Common Value | -477,438 | -175,000 | -172.8% |
| Retained Earnings | 679,504 | 445,945 | +52.4% |
| Accumulated Other Comprehensive Income | -1,307 | -1,615 | +19.1% |
| Total Stockholders' Equity | 1,089,797 | 1,088,011 | +0.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,307 | -1,615 | +19.1% |
| Additional Paid In Capital | 888,320 | 817,972 | +8.6% |
| Common Stock | 718 | 709 | +1.3% |
| Retained Earnings | 679,504 | 445,945 | +52.4% |
| Treasury Stock Common | -477,438 | -175,000 | -172.8% |
| Total Liabilities & Equity | 2,227,399 | 1,980,340 | +12.5% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation Amortization And Accretion Net | 70,098 | 64,624 | +8.5% |
| Asset Retirement Obligation Adjustment To Fair Value | -4,727 | — | — |
| Amortization of Financing Costs | 4,457 | 4,296 | +3.7% |
| Change In Fair Value Of Contingent Assets And Liabilities | 1,379 | -2,699 | +151.1% |
| Inventory Write Down | 2,202 | -904 | +343.6% |
| Stock-Based Compensation | 85,563 | 76,393 | +12.0% |
| Gain On Sale Of R E L I S T O R Licensed Intangible Asset | -5,000 | — | — |
| Equity Securities Fv Ni Unrealized Gain Loss | 8,617 | 43,564 | -80.2% |
Show Ownership breakouts |
|||
| Perspective Therapeutics, Inc | -5.1 | -41 | +87.6% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Radiopharm Theranostics Limited | -3.3 | -2.6 | -26.9% |
| Business Combination Increase Decrease In Acquired Intangible Assets | 11,212 | 66,000 | -83.0% |
| Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit | 21,595 | -30,029 | +171.9% |
| Change in Other Liabilities | 246 | 5,236 | -95.3% |
| Other Non-Cash Items | 5,174 | 12,194 | -57.6% |
| Change in Accounts Receivable | -17,888 | -37,685 | +52.5% |
| Change in Inventory | -9,366 | -2,670 | -250.8% |
| Increase Decrease In Other Operating Assets | -5,406 | 4,440 | -221.8% |
| Change in Accounts Payable | -2,492 | -8,804 | +71.7% |
| Increase Decrease In Accrued Liabilities | -9,082 | 46,767 | -119.4% |
| Net Cash from Operations | 390,141 | 544,750 | -28.4% |
| Deferred Income Taxes | 21,595 | -30,029 | +171.9% |
| Investing Activities | |||
| Payments For Capital Improvements | -36,089 | -51,625 | +30.1% |
| Payments To Acquisition Of In Process Research And Development | -5,413 | — | — |
| Payments To Acquire Businesses Net Of Cash Acquired (FY) | — | — | — |
Show Business Acquisition breakouts |
|||
| Evergreen Theragnostics | -268,933 | — | — |
| Life Molecular Imaging Ltd | -306,733 | — | — |
| Payments To Acquire Equity Securities Fv Ni | -10,000 | -83,246 | +88.0% |
| Net Cash from Investing | -627,168 | -226,015 | -177.5% |
| In Process Research And Development Included In Liabilities | 5,799 | — | — |
| Contingent Consideration Liabilities Related To Acquisitions | 96,842 | — | — |
| Lease Modification | 5,789 | — | — |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 2,770 | 63 | +4296.8% |
| Right Of Use Asset Obtained In Exchange For Finance Lease Liability | 711 | 514 | +38.3% |
| Share Repurchase Program Excise Tax Payable | 2,421 | 251 | +864.5% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -1,110 | -318 | -249.1% |
| Proceeds From Stock Options Exercised | 7,154 | 3,278 | +118.2% |
| Proceeds From Stock Plans | 3,727 | 3,450 | +8.0% |
| Tax Withholding for Share Compensation | -26,338 | -22,615 | -16.5% |
| Share Repurchases | -300,017 | -100,000 | -200.0% |
| Net Cash from Financing | -316,584 | -118,536 | -167.1% |
| Supplemental | |||
| Interest Paid | 15,094 | 15,094 | 0.0% |
| Income Taxes Paid | 69,037 | 153,815 | -55.1% |
| Unpaid Capital Expenditures | 3,445 | 5,058 | -31.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -49 | -998 | +95.1% |
| Net Change in Cash | -553,660 | 199,201 | -377.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 360,826 | 914,486 | -60.5% |
| Restricted Cash And Cash Equivalents | 1,705 | 1,672 | +2.0% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.